← FDA Drug Approvals (Drugs@FDA)
REGADENOSON
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: GLAND · Approved 2022-07-12
Drug application
- FDA Application #
ANDA207320- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- REGADENOSON
- Generic name
- REGADENOSON
- Active ingredients
- REGADENOSON
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Marketing status
- Prescription
- Sponsor
- GLAND
- Manufacturer
- Almaject, Inc.
- First approval
- 2022-07-12
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown